MF-1305 / Epirium Bio - LARVOL DELTA

Epirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week 2026 (Yahoo Finance) - "All doses of MF-300 significantly improved endoscopic measures of colitis severity, matching the response observed with the anti-p40 antibody positive control, a class of biologics used clinically in IBD that targets IL-12/23 signaling; All doses of MF-1305 improved DAI scores, comparable to the cyclosporine positive control, an established immunosuppressant used in IBD. MF-1305 also reduced inflammatory cytokines and improved histology scores, even exceeding the effects of cyclosporine in some endpoints."

Preclinical • Ulcerative Colitis